Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

NCT06056895 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06056895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06056895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 8, 2023
Completion date
April 30, 2027
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv merkel cell carcinoma ajcc v8, merkel cell carcinoma, unresectable clinical stage iii merkel cell carcinoma ajcc v8